Oct. 26 at 2:39 AM
$IQV "Heads up alert! Only three days until Upcoming earnings on Tuesday, 10/28/2025 for
$IQV
Neutral (5.8)
---
In recent evaluations of IQVIA Holdings (IQV), the company has demonstrated a mixed financial landscape characterized by both positive growth indicators and prevailing industry challenges.
The stock has experienced a notable increase of approximately 39.8% over the past six months, outperforming the S&P 500 by 11.8%.
Currently, IQV trades around
$200.20, with a consensus analyst price target rising slightly to
$223, reflecting a cautious optimism about its operational stability and diversified service offerings.
Key financial metrics reveal a P/E ratio of approximately 25, which is competitive within the healthcare analytics sector, though slightly above the industry average of around 22.
Additionally, IQV's recent earnings per share (EPS) growth has shown promise, with projections indicating steady single-digit increases in profitability.
Revenue forecasts suggest continued strength driven by biopharma services, despite headwinds related to the offloading of COVID-related inventories.
Comparatively, IQVIA's performance is solid, although it has not fully matched the growth rates of some industry peers that are capitalizing on emerging market trends.
Looking ahead, IQVIA is set to announce its Q3 earnings on October 28, 2025, with analysts expecting revenues and EPS to rise, driven by effective cost controls and biopharma strength.
Historical performance indicates that IQV has a mixed track record of beating estimates, which could influence market sentiment post-announcement.
The consensus among analysts remains cautiously optimistic, with a buy rating prevailing, although concerns about the broader healthcare sector's performance, which has trailed the S&P 500, may temper expectations.
The healthcare sector overall has returned 13.5% over the past six months, significantly lagging the S&P 500 by 9.4 percentage points, indicating a challenging environment for companies like IQV that are navigating operational pressures while seeking growth opportunities.
- Funds were net buyers of
$IQV during the previous reporting quarter.
- Funds with large holdings in
$IQV include:
- Canada Pension , MV:
$657MM. Fund Rank: 78%
- Farallon Capital Management LLC, MV:
$607MM. Fund Rank: 70%
www.faralloncapital.com
- Cantillon Captal Management LLC, MV:
$239MM. Fund Rank: 76%
www.cantillon.com
- Alyeska Investments, MV:
$118MM. New position. Fund Rank: 79%
- Cadian Capital Management LP, MV:
$103MM. Fund Rank: 87%
www.cadiancap.com
- Last 10 days performance: 8%
- Last 30 days performance: 22%
- Last 90 days performance: 11%
Some of the latest news articles:
- Title: 3 Healthcare Stocks Walking a Fine Line
Publication Date: 10/24/2025 4:39:44 AM, Source: yahoo
URL: https://finance.yahoo.com/news/3-healthcare-stocks-walking-fine-043944631.html?.tsrc=rss
- Title: IQVIA Gears Up to Report Q3 Earnings: What's in the Cards?
Publication Date: 10/23/2025 2:19:00 PM, Source: yahoo
URL: https://finance.yahoo.com/news/iqvia-gears-report-q3-earnings-141900716.html?.tsrc=rss
- Title: What Catalysts Could Shift the Narrative for IQVIA Amid New Analyst Insights and Partnerships
Publication Date: 10/23/2025 7:13:00 AM, Source: yahoo
URL: https://finance.yahoo.com/news/catalysts-could-shift-narrative-iqvia-071300008.html?.tsrc=rss
- Title: TransMedics (TMDX) Reports Next Week: Wall Street Expects Earnings Growth
Publication Date: 10/22/2025 2:00:33 PM, Source: yahoo
URL: https://finance.yahoo.com/news/transmedics-tmdx-reports-next-week-140033829.html?.tsrc=rss
Follow us on stocktwits.com for more earnings alerts. Not a financial advice. Not a trading signal."
